01—Abstract
Summary
Summary of the 10-K filed February 17, 2009. Cited figures are marked; the original filing is the authoritative source.
Vertex Pharmaceuticals' 2008 10-K (filed February 17, 2009) describes a company whose value rests almost entirely on telaprevir, an oral hepatitis C protease inhibitor in Phase 3 development.
The company remains pre-revenue on a product basis and reported a 2008 net loss of $459.9 milliona ($3.27 per share), up 18% from $391.3 million in 2007. Total revenues fell 12% to $175.5 million, driven by the May 2008 sale of its HIV royalty stream (Lexiva/Telzir) to Fosamprenavir Royalty for $160.0 million, and by lower CFFT collaboration revenue. Janssen supplied 68% of 2008 revenue, and the company expects Janssen-related revenue to decline in 2009 as milestone payments wind down.
Financially, Vertex strengthened its balance sheet in 2008, ending the year with $832.1 millionb in cash, cash equivalents and marketable securities, up from $467.8 million, after a $391.3 million equity and convertible note raise in February, a $217.4 million equity offering in September, and the royalty sale. Offsetting this, the company took on $287.5 million of 4.75% convertible notes due 2013, and stockholders' equity fell to $238.9 million from $271.3 million as accumulated losses mounted. Management states that current resources, plus expected collaborator payments, should fund operations for at least twelve months, but it expects to need additional capital to complete telaprevir development and commercialization and has not provided a timeline for profitability.
Key catalysts and risks lie ahead. The ADVANCE (treatment-naive) and REALIZE (treatment-experienced) Phase 3 trials completed enrollment in late 2008 and early 2009, with SVR data expected in the first half of 2010 and an NDA targeted for the second half of 2010.
Competitor Schering-Plough's boceprevir could reach the market on a comparable timeline, and the company faces significant commercial-supply investment, a planned sales-force build, and leadership transition (Matthew Emmens becomes CEO in May 2009). Investors should weigh the binary nature of telaprevir's Phase 3 outcome against the company's substantial cash runway and ongoing collaboration support.
02—Key points
Key Highlights
- Net loss widened to $459.9 million in 2008 (from $391.3 million in 2007), or $3.27 per share, with R&D expenses of $516.3 million remaining the dominant cost.
- Total revenues declined 12% to $175.5 million, largely because the May 2008 sale of HIV royalty rights removed future cash royalties from GlaxoSmithKline's Lexiva/Telzir.
- Cash, cash equivalents and marketable securities rose to $832.1 million at year-end 2008, supported by roughly $900 million in equity and debt raises and the $160.0 million royalty sale.
- Telaprevir Phase 3 programs (ADVANCE, REALIZE, ILLUMINATE) completed enrollment; SVR data expected in 1H 2010 and NDA submission planned for 2H 2010.
- Janssen accounted for 68% of 2008 total revenues; the $165.0 million 2006 up-front payment and milestones (up to $380.0 million) underpin the collaboration economics.
- Competitive risk from Schering-Plough's boceprevir, which could reach the market on a comparable timeline to telaprevir.
- New $287.5 million 4.75% convertible notes due 2013 added fixed-rate debt service, while stockholders' equity declined to $238.9 million.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2008filed February 17, 2009Financial Statements
| Revenue | $175.50M |
| R&D Expenses | $516.91M |
| SG&A Expenses | $101.29M |
| Operating Expenses | $638.21M |
| Operating Income | -$462.71M |
| Interest Expense | $13.47M |
| Net Income | -$459.85M |
| EPS (Basic) | $-3.27 |
| EPS (Diluted) | $-3.27 |
| Shares Outstanding (Basic) | 140.56M |
| Shares Outstanding (Diluted) | 140.56M |
05—Questions
Frequently Asked Questions
Why did Vertex's revenue decline in 2008, and is that trend expected to continue?
Revenue fell 12% to $175.5 million because the company sold its right to future HIV royalty payments (Lexiva/Telzir) for $160.0 million in May 2008, and because CFFT collaboration revenue ended. Management expects Janssen-related revenue to decrease in 2009 as the principal remaining milestones relate to European filing and launch, while some deferred royalty revenue from the sale will continue to be recognized.
When could telaprevir reach the market, and what must happen first?
Vertex plans to file a U.S. NDA in the second half of 2010, contingent on successful completion of the registration program. SVR data from ADVANCE and REALIZE are expected in the first half of 2010, and the FDA has granted Fast Track designation. Approval, commercial supply, and a sales force build-out are all still ahead, and the company faces the risk that Schering-Plough's boceprevir could be approved on a similar timeline.
Does Vertex have enough cash to fund operations?
Management believes its $832.1 million in cash and marketable securities, together with expected collaborator payments, is sufficient for at least the next twelve months. However, the company expects to need additional capital to complete telaprevir development and commercialization and to advance VX-770, and it may raise funds through equity, debt, or collaborations, which could dilute shareholders or require relinquishing rights to assets.
What are the main risks around the VX-770 cystic fibrosis program?
VX-770's registration program is based primarily on a 39-patient Phase 2a trial with short dosing periods (14 and 28 days). The company must demonstrate safety and efficacy in a larger population over longer durations, and must also study pediatric patients and F508del patients, who are not covered by the initial data. The company expects to begin the registration program in the first half of 2009.
06—Continue